Key Takeaways SMMT's Q2 loss per share widened to $0.76, missing the consensus estimate of a loss of $0.10.Higher R&D costs stemmed from expanded ivonescimab trials for non-small cell lung cancer.FDA requires OS benefit before approving ivonescimab-chemo for EGFR-mutated lung cancer.Summit Therapeutics (SMMT) reported second-quarter 2025 loss per share of 76 cents, much wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company had incurred a loss of 9 cents.The repor ...